Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) and PLx Pharma (NASDAQ:PLXP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.
Valuation & Earnings
This table compares Kiora Pharmaceuticals and PLx Pharma’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiora Pharmaceuticals | $10,000.00 | 442.98 | -$13.58 million | N/A | N/A |
| PLx Pharma | $4.54 million | 0.13 | -$46.13 million | ($1.85) | -0.01 |
Kiora Pharmaceuticals has higher earnings, but lower revenue than PLx Pharma.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiora Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| PLx Pharma | 0 | 0 | 0 | 0 | N/A |
Kiora Pharmaceuticals currently has a consensus target price of $46.00, indicating a potential upside of 7,428.64%.
Volatility & Risk
Kiora Pharmaceuticals has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, PLx Pharma has a beta of 3.79, suggesting that its share price is 279% more volatile than the S&P 500.
Profitability
This table compares Kiora Pharmaceuticals and PLx Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiora Pharmaceuticals | N/A | -93.39% | -58.70% |
| PLx Pharma | -606.91% | -291.11% | -119.43% |
Insider and Institutional Ownership
13.9% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 21.2% of PLx Pharma shares are held by institutional investors. 0.9% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 9.0% of PLx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Kiora Pharmaceuticals beats PLx Pharma on 6 of the 10 factors compared between the two stocks.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
About PLx Pharma
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
